Neuroactive steroids: Potential therapeutic use in neurological and psychiatric disorders

Trends in Pharmacological Sciences

Volumn 20, Issue 3, 1999, Pages 107-112

  Gasior, Maciej ^a   Carter, Richard B ^b   Witkin, Jeffrey M ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b Department of Pharmacokinetics and Drug Metabolism   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXY 3BETA TRIFLUOROMETHYL 19 NOR 5BETA PREGNAN 20 ONE; 3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; CO 26749; GANAXOLONE; STEROID; UNCLASSIFIED DRUG;

ANXIETY NEUROSIS; DRUG STRUCTURE; DRUG USE; EPILEPSY; HUMAN; INSOMNIA; MENTAL DISEASE; MIGRAINE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEIZURE;

ANIMALS; HUMANS; NERVOUS SYSTEM DISEASES; PSYCHOTROPIC DRUGS; RECEPTORS, GABA-A; STEROIDS;

EID: 0032983002     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(99)01318-8     Document Type: Review

References (60)

1. Gee, K. W., McCauley, L. D. and Lan, N. C. (1995) Crit. Rev. Neurobiol. 9, 207-227
2. Lambert, J. J. et al. (1995) Trends Pharmacol. Sci. 16, 295-303
3. Rupprecht, R. (1997) J. Psychiatr. Res. 31, 297-314
4. McNamara, J. O., Bonhaus D. W. and Shin, C. (1993) in Epilepsy: Models, Mechanisms and Concepts (Schwartzkroin, P. A., ed.), pp. 27-47, Cambridge University Press
5. Shinnar, S. and Berg, A. T. (1996) Epilepsia 37, 701-708
6. Belelli, D., Lan, N. C. and Gee, K. W. (1990) Neurosci. Biobehav. Rev. 14, 315-322
7. Kokate, T. G., Svensson, B. E. and Rogawski, M. A. (1994) J. Pharmacol. Exp. Ther. 270, 1223-1229
8. Carter, R. B. et al. (1997) J. Pharmacol. Exp. Ther. 280, 1284-1295
9. Gasior, M. et al. (1997) J. Pharmacol. Exp. Ther. 282, 543-553
10. Kokate, T. G. et al. (1996) Neuropharmacology 35, 1049-1056
11. Gasior, M. et al. (1998) Drug Dev. Res. 44, 21-33
12. Monaghan, E. P. et al. (1997) Epilepsia 38 (Suppl. 8), 179
13. Shields, W. D. et al. (1997) Ann. Neurol. 42, 503-504
14. Wieland, S. et al. (1991) Brain Res. 565, 263-268
15. Crawley, J. N. et al. (1986) Brain Res. 398, 382-385
16. Wieland, S. et al. (1995) Psychopharmacology 118, 65-71
17. Brot, M. D. et al. (1997) Eur. J. Pharmacol. 325, 1-7
18. Edgar, D. M. et al. (1997) J. Pharmacol. Exp. Ther. 282, 420-429
19. Abrol, S. et al. (1997) Soc. Neurosci. Abstr. 23, 960
20. Rodgers, R. J. and Johnson, N. J. T. (1998) Pharmacol. Biochem. Behav. 59, 221-232
21. Bitran, D., Hilvers, R. J. and Kellog, C. K. (1991) Brain Res. 561, 157-161
22. Vivian, J. A. et al. (1997) J. Pharmacol. Exp. Ther. 282, 318-325
23. Zimmerberg, B., Brunelli, S. A. and Hofer, M. A. (1994) Pharmacol. Biochem. Behav. 47, 735-738
24. Picazo, O. and Fernández-Guasti, A. (1995) Brain Res. 680, 135-141
25. Beekman, M. et al. (1998) J. Pharmacol. Exp. Ther. 284, 868-877
26. Lancel, M. (1997) J. Pharmacol. Exp. Ther. 282, 1213-1218
27. Barbaccia, M. L. et al. (1997) Br. J. Pharmacol. 120, 1582-1588
28. Mendelson, W. B. et al. (1987) Psychopharmacology 93, 226-229
29. Limmroth, V. et al. (1996) Br. J. Pharmacol. 117, 99-104
30. Moskowitz, M. A. et al. (1998) Am. Assoc. Stud. Headache Syllabus
31. Data, J. et al. (1998) Am. Assoc. Stud. Headache Syllabus
32. Devaud, L. L., Purdy, R. H. and Morrow, A. L. (1995) Alcohol Clin. Exp. Res. 19, 350-355
33. Finn, D. A., Roberts, A. J. and Crabbe, J. C. (1995) Alcohol Clin. Exp. Res. 19, 410-415
34. Devaud, L. L. et al. (1996)J. Pharmacol. Exp. Ther. 278, 510-517
35. Reddy, D. S. and Kulkarni, S. K. (1997) Eur. J. Pharmacol. 337, 19-25
36. Budziszewska, B., Jaworska-Feil, L. and Lason, W. (1996) Eur. Neuropsychopharmacol. 6, 135-140
37. Reddy, D. S. and Kulkarni, S. K. (1997) Methods Find. Exp. Clin. Pharmacol. 19, 395-405
38. Rogawski, M. A. and Porter, R. J. (1990) Pharmacol. Rev. 42, 223-285
39. Dhuna, A. et al. (1991) Neurotoxicology 12, 621-626
40. Rogawski, M. A. (1996) in Neurotherapeutics: Emerging Strategies (Pullan, L. and Patel, J., eds), pp. 193-273, Humana Press
41. Frye, C. A. (1995) Brain Res. 696, 113-120
42. Schumacher, M., Robel, P. and Baulieu, E. E. (1996) Dev. Neurosci. 18, 6-21
43. Monaghan E. P. et al. (1997) Epilepsia 38, 1026-1031
44. AReceptors and Anxiety: From Neurobiology to Treatment (Biggio, G., Sanna, E. and Costa, E., eds), pp. 135-152, Raven Press
45. Baldessarini, R. J. (1996) in Goodman and Gilman's The Pharmacological Basis of Therapeutics (9th edn) (Hardman, J. G. et al., eds), pp. 399-430, McGraw-Hill
46. Miczek, K. A. et al. (1997) in Recent Developments in Alcoholism (Vol. 13) Alcoholism and Violence (Galanter, M., ed.), pp. 139-171, Plenum Press
47. Britton, K. T. et al. (1991) J. Pharmacol. Exp. Ther. 258, 124-129
48. Wieland, S. et al. (1997) Psychopharmacology 134, 46-54
49. Lancel, M. et al. (1996) Am. J. Physiol. 271, E763-E772
50. Friess, E. et al. (1997) Am. J. Physiol. 272, E885-E891
51. Hill-Venning, C. et al. (1996) Neuropharmacology 35, 1209-1222
52. Sear, J. W. (1998) Eur. J. Anaesthesiol. 15, 129-132
53. Bradley, W. G. et al. (1968) Br. Med. J. 3, 531-533
54. Lundberg, P. O. (1968) Acta Neurol. Scand. 45, 309-326
55. Chen, T. and Leviton, A. (1994) Headache 34, 107-110
56. Emmett-Oglesby, M. W. et al. (1990) Psychopharmacology 101, 292-309
57. Marshall, F. H. et al. (1997) Pharmacol. Biochem. Behav. 58, 1-8
58. Vanover, K. E. et al. (1999) Psychopharmacology 141, 77-82
59. Finn, D. A. et al. (1997) Pharmacol. Biochem. Behav. 56, 261-264
60. Winger, G. et al. (1996) Behav. Pharmacol. 7 (Suppl. 1), 121